Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.78 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | APP | P05067 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11332310 | 0.91 | KMT2A (0.73) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL31061375 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL4364384 | 0.88 | CXCR2 (0.74) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL14514336 | 0.88 | NPC1 (0.64) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL7491596 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL1311622 | 0.88 | CXCR1 (0.62) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL5852169 | 0.88 | LMNA (0.68) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL15306504 | 0.87 | CXCR2 (0.65) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL4121951 | 0.84 | ABCG2 (0.67) | CXCR2CXCR1LMNAMAPTALDH1A1 | |
| SCHEMBL113558 | 0.82 | MEN1 (0.71) | LMNAMAPTALDH1A1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0496595-B1 | Aniline derivatives and process for producing the same | NISSAN CHEMICAL IND LTD (JP) | 1995-09-06 | — | — | EP | claimed |
| US-5416236-A | Sulfonylation, reduction and carbamylation in multistage process | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-16 | — | — | US | claimed |
| EP-0496595-A1 | Aniline derivatives and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1992-07-29 | — | — | EP | claimed |
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2013-10-10 | — | — | US | disclosed |
| US-7629002-B2 | Antimicrobial polymeric compositions and method of treatment using them | CHEMEQ LTD. (AU) | 2009-12-08 | — | — | US | disclosed |
| EP-1474155-A4 | METHOD OF TREATMENT OF GASTROINTESTINAL DISEASE AND POLYMERIC COMPOSITION FOR USE THEREIN | CHEMEQ LTD (AU) | 2008-04-16 | — | — | EP | disclosed |
| EP-1474155-A1 | METHOD OF TREATMENT OF GASTROINTESTINAL DISEASE AND POLYMERIC COMPOSITION FOR USE THEREIN | CHEMEQ LTD. (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20030195131-A1 | Antimicrobial polymeric compositions and method of treatment using them | CHEMEQ LTD. (AU) | 2003-10-16 | — | — | US | disclosed |
| WO-2003061672-A1 | METHOD OF TREATMENT OF GASTROINTESTINAL DISEASE AND POLYMERIC COMPOSITION FOR USE THEREIN | CHEMEQ LTD (AU) | 2003-07-31 | — | — | WO | disclosed |
| US-6268496-B1 | GAMMA-AMINOBUTYRIC ACID RECEPTOR LIGANDS | NEUROGEN CORPORATION | 2001-07-31 | — | — | US | disclosed |
| EP-0555391-B1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5744602-A | PSYCHOLOGICAL DISORDERS, ANTICONVULSANTS | NEUROGEN CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0496595-B1 | Aniline derivatives and process for producing the same | NISSAN CHEMICAL IND LTD (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5416236-A | Sulfonylation, reduction and carbamylation in multistage process | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0555391-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0496595-A1 | Aniline derivatives and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5130430-A | Anxiety, sleep disorders or seizures | NEUROGEN CORPORATION (US) | 1992-07-14 | — | — | US | disclosed |
| WO-1992007853-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | NAAA, AADAC, NISCH | CXCR2 4070/4885CXCR1 4077/4885LMNA 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.